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ing frequently in missed diagnosis since the disease itself is a rare one. The aim of the study is to
establish a new reliable and accurate laboratory method for separation, identiﬁcation and quanti-
tation of urinary porphyrins by liquid chromatography tandem mass spectrometry (LC/MS/MS)
and thereby the diagnosis of different porphyria types for the ﬁrst time in Egypt. Screening by
plasma ﬂuorescence and quantitative determination of urinary porphyrins by high performance
liquid chromatography electrospray ionization tandem mass spectrometry (HPLC/ESI/MS/MS)
of 50 clinically suspected patients revealed one case of variegate porphyria and ﬁve cases of por-
phyria cutanea tarda. Plasma ﬂuorescence scanning is a simple procedure that can be used as
screening test to detect porphyria patients that require quantitation of urinary porphyrins as a
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50 E. Fateen et al.mapping techniques are applicable for the differential diagnosis of porphyria types, since each type
has a characteristic porphyrins excretion proﬁle. Quantitative determination of urinary porphyrins
by HPLC/ESI/MS/MS used in this study is a modiﬁcation for the method Stoev et al. while ion
mapping technique is a new technique invented by the research team at the Biochemical Genetics
Department.
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Porphyrias are a group of seven inherited and acquired meta-
bolic disorders of haem biosynthesis including aminolevulinic
acid dehydratase porphyria (ADP), acute intermittent por-
phyria (AIP), variegate porphyria (VP), hereditary copropor-
phyria (HCP), porphyria cutanea tarda (PCT), erythropoietic
protoporphyria (EPP) and congenital erythropoietic por-
phyria (CEP). Each results from a speciﬁc enzymatic alter-
ation in the heam biosynthesis pathway. Speciﬁc patterns of
accumulation of the haem precursors 5-aminolevulinic acid,
porphobilinogen and porphyrins are associated with charac-
teristic clinical features: acute neurovisceral attacks, skin le-
sions or both. Eight enzymes bring about haem synthesis
from glycine and succinyl CoA. The biosynthetic pathway be-
gins in the mitochondria and after three cytoplasmic stages
the ﬁnal step of haem formation takes place again in the mito-
chondria [1].
Although haem is synthesized in every human cell for respi-
ratory and oxidation-reduction reactions, it is mostly produced
in the erythropoietic cells for haemoglobin synthesis and the li-
ver parenchymal cells for synthesis of cytochromes and haemo-
proteins. Control of haem production differs between these two
tissues, mostly because of differences in rates of synthesis of 5-
aminolevulinic acid. The ﬁrst enzyme, 5-aminolevulinic acid
synthase (ALAS), is coded by two genes: one erythroid speciﬁc
(ALAS2 on chromosome X) and one ubiquitous (ALAS1 on
chromosome 3). ALAS1 is the rate limiting enzyme in the pro-
duction of haem in the liver and is controlled via negative feed-
back regulation by the intracellular uncommitted haem pool
[2].
In erythroid cells, synthesis of haem is regulated during ery-
throid differentiation in response to erythropoietin. In these
cells, ALAS2 synthesis is induced only during active haem syn-
thesis. The rate is limited by iron availability and is not inhib-
ited by haem [3]. Spleen and liver macrophages degrade haem
and recycle iron after erythrophagocytosis through inducible
haem oxygenase 1. Porphyrias are often classiﬁed as hepatic
or erythropoietic according to the organ in which haem pre-
cursors accumulate. However, a classiﬁcation as acute porphy-
rias, cutaneous porphyrias, and rare recessive porphyrias
based on clinical presentation is directly related to a simple
biological diagnosis strategy and is more practical than are
other classiﬁcations [4].
People with autosomal-dominant acute porphyrias––
aminolevulinic acid dehydratase porphyria, acute intermittent
porphyria, variegate porphyria, and hereditary copropor-
phyria––can present with a sudden life threatening crisis. These
attacks are infrequent because penetrance is low and they are
difﬁcult to diagnose because they are non-speciﬁc. Acute at-
tacks happen in all acute porphyrias. Skin lesions never devel-
op in acute intermittent porphyria but are the only clinical
manifestation in some patients with variegate porphyria(60% of patients), and rarely (5%) develop in patients with
hereditary coprophorphyria [1].
Porphyric attacks begin with a prodromic phase including
minor behavioural changes such as anxiety, restlessness, and
insomnia [5]. Most people with acute attacks present with se-
vere abdominal pain, but this pain might also be felt in the
back or thighs. Nausea, vomiting, and constipation are com-
mon. Tachycardia, excess sweating, and hypertension, which
are symptoms of increased sympathetic activity, are often pres-
ent [6].
Variegate porphyria, hereditary coproporphyria, and por-
phyria cutanea tarda share the same chronic cutaneous photo-
sensitivity. Lesions are restricted to sun-exposed areas such as
the backs of the hands, face and neck; some women might also
develop lesions on the legs and feet. Skin fragility is perhaps
the most speciﬁc feature, in which negligible trauma is fol-
lowed by superﬁcial erosion that is soon covered by a crust [7].
Haemodialysis in patients with chronic renal failure can
predispose to this disorder, but in chronic renal failure and
end-stage liver disease, skin blisters resembling those of por-
phyria cutanea tarda and often referred to as pseudoporphyria
can develop [8].
Erythropoietic protoporphyria is an inherited disorder that
is caused by partial deﬁciency in mitochondrial ferrochelatase.
Accumulation of free protoporphyrin, mainly in erythrocytes
and secondarily in other tissues (skin and liver) or biological
ﬂuids (bile and faeces), leads to painful photosensitivity and po-
tential liver complications. The most common clinical manifes-
tation is seasonal lifelong acute photosensitivity of sun-exposed
skin. Many patients have a slight microcytic, hypochromic ane-
mia [9].
Congenital erythropoietic porphyria (or Gunther disease) is
the most frequent of the rare recessive porphyrias. Most pa-
tients have severe photosensitivity, leading to bullae, scarring,
and eventually disﬁgurement of the light-exposed parts of the
body such as hands, ears, nose, and eyelids. Ocular involve-
ment includes chronic ulcerative keratitis and corneal scarring
[10].
The aim of the study is to establish a new reliable and accu-
rate laboratory method for separation, identiﬁcation and
quantitation of urinary porphyrins by liquid chromatography
tandem mass spectrometry (LC/MS/MS) and thereby the diag-
nosis of different porphyria types for the ﬁrst time in Egypt.
2. Patients and methods
Fifty cases suspected to have porphyria were selected from pa-
tients attending Cairo University pediatrics hospital and clini-
cal genetics department’s clinic, National Research Centre
including:
– Nine patients having neurological manifestations without
skin manifestations: Neurological manifestations presented
Table 1 Mass-to-charge ratio (m/z) of porphyrins and their
fragments.
Name of porphyrin Molecular mass [M+ 1] Daughter m/z
Porphobilinogen 226 227 210
Pentacarboxylporphyrin 698 699 640–596
Hexacarboxylporphyrin 742 743 639–684–699
Coproporphyrin I 654 655 596–537
Uroporphyrin I 830 831 727–785–767
Porphyrins proﬁle by high performance liquid chromatography/electrospray 51as convulsions (100%), polyneuropathy (33%), spastic
muscle tone (88%) and abdominal pain (22%), white mat-
ter demyelination on magnetic resonance imaging (55%).
– Eight patients having neurological manifestations with skin
manifestations: Neurological manifestations presented as
convulsions (75%), polyneuropathy (37.5%) and abdomi-
nal pain (50%). Skin manifestations presented as dry skin
(37.5%), itching attacks (62.5%) and photosensitivity
(12.5%).
– Thirteen patients having erythropoietic manifestations and
presented with anemia (100%), splenomegaly (30%) and
hepatomegaly (46%).
– Sixteen patients having chronic liver disease and presented
with hepatomegaly (100%), anemia (87.5%), lesions on
sun exposed areas especially arms and legs and skin fragility
(31.8%).
– Four patients having chronic renal disease and presented
with abdominal pain (100%), skin lesions and blisters in
sun exposed areas (50%) and high levels of creatinine and
urea (100%): 25 healthy subjects of matching age and sex
were also included for comparison as controls.
All patients were subjected to complete history taking and
physical examination.
2.1. Plasma ﬂuorescence scanning
For screening of porphyria using plasma by the method of
Poh-Fitzpatrick [11]: 1 ml of plasma was diluted with 9 ml of
phosphate-buffered saline (pH 7.4). A ﬂuorescence spectro-
photometer (Hitachi 650-109 ﬂuorescence spectrophotometer)
equipped with a red-sensitive photomultiplier and chart recor-
der spectrophotometer was zeroed against phosphate-buffered
saline at an excitation wavelength of 405 nm and emission
wavelength of 620 nm, with the monochromator slit width
set at 5 nm. The emission spectrum was then scanned from
550 to 650 nm with the excitation monochromator set at
405 nm. The products of addition of known coproporphyrin
I, uroporphyrin I and protoporphyrin IX to normal human
plasma was similarly diluted and scanned.
2.2. Quantitation of urinary porphyrins by high performance
liquid chromatography (HPLC) mass spectrometry (tandem
mass)
Coproporphyrin I dihydrochloride, Uroporphyrin I dihydo-
chloride, 5-carboxylporphyrin dihydrochloride, 6-carbo-
xylporphyrin dihydrochloride and porphobilinogen used as
standards were purchased from Frontier Scientiﬁc Inc. Logan,
USA. Working solutions of standards were prepared by dis-
solving in HPLC grade methanol for construction of calibra-
tion curve.
Extraction of porphyrins from urine was done by mixing
of 1 ml of urine with 40 ll of concentrated HCl and centri-
fuged. The supernatant was used for analysis by LC/MS/
MS [12].
2.2.1. Instrumentation
2.2.1.1. Liquid chromatography tandem mass spectrometry
(LC–MS–MS) system. Thermo ion trap mass spectrometer
LCQ ADVANTAGE MAX coupled to a modular surveyor
LC system was used for the identiﬁcation of porphyrins. TheLC system includes LC pump, autosampler and photodiode
Array detector (PDA). The software linked to the instrument
is Xcalibur, Version 1.1 (Thermo Finnigan Company).
2.2.2. High performance liquid chromatography tandem mass
spectrometry (HPLC/MS/MS) method
The used LC column was Inertsil ODS-2 C18, 150 mm ·
2.1 mm with a Synergy C18, 4.0 mm · 2.0 mm precolumn. A
ternary mobile phase and a gradient elution were used at a ﬂow
rate of 0.25 ml/min. mobile phases used were A: 20 mM
Ammonium acetate buffer, B: acetonitrile and C: methanol.
The elution system was: 0–17 min, 90% A, 5% B, 5% C; 17–
30 min, 30% A, 50% B, 20% C; 30–33 min; 10% A, 60% B,
30% C; 33–34 min, 90% A, 5% B, 5%C. The PDA detector
was set to scan in the wavelength range 250–600 nm and the
mass detector range was 150–900 m/z. The sample injection
volume was 10 ll [13].
We used ESI mode: sheath gas–nitrogen (6 l/min); the tem-
perature and the voltage of the heated capillary were 300 C
and 25 V, respectively and tube lens offset 5 V. Helium was
used as a collision gas [13]. Triple fragmentation mass spec-
trometry (MS3) was done on the positive mode at collision en-
ergy 45%. The masses of porphyrins and their MS3 fragments
are shown in Table 1 [14].2.2.3. Quantitative determination of porphyrins proﬁle
Calibration curve for each standard was plotted as a response
(peak area) versus concentration. Using these curves, quantita-
tion of porphyrins in urine samples (unknowns) can be pro-
cessed Xcalibur, Version 1.1. software.2.2.4. Ion mapping method
Another comparative method was applied using mass spec-
trometer detector without HPLC system. Infusion experiments
were performed using syringe pump (Hamilton syringe, 500 ll)
directly connected to the electospray ionization (ESI) at a ﬂow
rate 10 ll/min and run time 5 min.
We used ESI mode: sheath gas–nitrogen (6 l/min); the tem-
perature and the voltage of the heated capillary were 300 C
and 25 V, respectively and tube lens offset 5 V. Helium was
used as a collision gas. Fragmentation was done on the posi-
tive mode at collision energy 45%.
The technique used was Total Ion Mapping Experiment
where we get product ion scans for each parent ion, so we
can determine which parent ions lost a particular fragment
to yield a particular daughter ion. This technique is
applied for the ﬁrst time for determination of urinary
porphyrins.
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Fifty patients were included: in forty patients the age ranged
between 1 month and 27 month with mean age 8.75 ±
5.76 month, in ﬁve patients the age ranged between 5 years
and 12 years with mean age 9.6 ± 4.15 years and in ﬁve pa-
tients the age ranged between 31 years and 46 years with mean
age of 38.4 ± 6.02 years. Twenty ﬁve controls had age range
between 2 years and 24 years with mean age 10.36 ± 6.2 years.
Patients included 29 (58%) males and 21 (42%) females, while
controls were 14 males and 11 females (Fig. 1). The parents ofConsanguinity Percent 
56%
44%
Positive consanguinity
Negative consanguinity
Figure 1 Consanguinity percent in studied group.
58%42%
Male
Female
Male and female percent 
Figure 2 Percent of males and females in studied group.
Table 2 Age, sex, consanguinity and clinical manifestations of pos
Case no. Age (year) Sex Consanguinity Clinical manifestation
$ #
1 6
p
+ Polyneuropathy, abdomi
photosensitivity, dark ur
2 34
p
– Hepatomegaly, anemia,
conjunctiva, skin manife
3 39
p
– Hepatomegaly, anemia,
manifestations
4 31
p
– Hepatomegaly, anemia,
conjunctiva, skin manife
5 42
p
– Hepatomegaly, anemia,
manifestations
6 46
p
+ Hepatomegaly, anemia,
manifestations28 (56%) patients were consanguineous compared to 13 (52%)
controls (Fig. 2).
One case (2% out of 50 suspected patients) and (12.5% out
of eight patients presented with neurological and skin manifes-
tations) was diagnosed with variegate porphyria, while ﬁve
cases (10% out of 50 suspected patients) and (31.2% out of six-
teen patients presented with chronic liver disease) were diag-
nosed to have porphyria cutanea tarda from (Tables 2 and 3).
Figs. 3 and 4 represent the ﬂuorescence emission spectrum
of normal plasma (no emission peak) and variegate porphyria
patient plasma (case no. 1) showing the emission peak at
625 nm while in porphyria cutanea tarda patients the emission
peak was at 620 nm.
Case no.one showed markedly increased urinary porphobi-
linogen and coproporphyrin levels which are shown in Figs. 5
and 6 respectively.
The other ﬁve diagnosed cases as porphyria cutanea tarda
showed markedly increased urinary uroporphyrin and 7-car-
boxylporphyrin levels which are shown in Figs. 7 and 8
respectively.
The six urinary porphyrin concentrations were calculated
using Xcalibur, Version 1.1 software. Peak area and calibra-
tion curve of coproporphyrin as an example is shown in Figs.
9 and 10.
4. Discussion
Porphyrias are a group of inherited or acquired disorders of
certain enzymes in the heme bio-synthetic pathway. They are
broadly classiﬁed as hepatic porphyrias and erythropoietic
porphyrias, based on the site of the overproduction and accu-
mulation of the porphyrins or their precursors [1]. Clinically
they are classiﬁed as acute and non acute (cutaneous) porphy-
rias. They manifest with either neurological complications or
skin problems or occasionally both [15]. Most symptoms
found in porphyrias are nonspeciﬁc and occur intermittently;
resulting in frequently missed diagnosis since the disease itself
is rather rare.
Laboratory tests can mostly conﬁrm or exclude the diagno-
sis of porphyria. The accumulation of porphyrin precursors or
porphyrins in each disorder can differentiate each type of
porphyria.
This study included 50 highly suspected cases of porphyria.
Positive consanguinity was found in 56% of the studied cases.itively diagnosed cases.
Family history Diagnosis
nal pain, skin
ine
– Variegate porphyria
dark urine, red
stations
– Porphyria cutanea tarda
dark urine, skin – Porphyria cutanea tarda
dark urine, red
stations
– Porphyria cutanea tarda
dark urine, skin – Porphyria cutanea tarda
dark urine, skin – Porphyria cutanea tarda
Table 3 Results of ﬂuorometric porphyria screening in plasma and quantitative determination of urinary porphyrins by LC/MS/MS
for positively diagnosed cases.
Case no. Fluorometric screening
of porphyria in plasma
Quantitative determination of porphyrins in urine by LC/MS/MS
Porpho-bilinogen 5 Carboxyl-
porphyrin
6 Carboxyl-
porphyrin
7 Carboxyl-
porphyrin
Uro-porphyrin Copro-
porphyrin
Meso-
porphyrin
1 +ve emission peak at 625 nm 115.3 (›) 1.2 2.7 1.5 36.8 420.6 (›) 5.4
2 +ve emission peak at 620 nm 21.3 3.4 4.2 29.5 (›) 201.3 (›) 180.4 2.9
3 +ve emission peak at 620 nm 17.11 3.6 5.9 15.5 (›) 133.5 (›) 170.5 5.7
4 +ve emission peak at 620 nm 2.4 4.6 2.8 18.4 (›) 125.6 (›) 185.3 4.5
5 + ve emission peak at 620 nm 12.7 0.9 4.1 23.1 (›) 212.8 (›) 182.4 5.8
6 +ve emission peak at 620 nm 20.4 6.1 1.5 12.8 (›) 115.3 (›) 190.1 3.6
Reference
range
0–25 lmol/l 0–8 nmol/l 0–8 nmol/l 0–9 nmol/l 0–60 nmol/l 0-200 nmol/L 0-8 nmol/L
5.00E+02
1.00E+03
1.50E+03
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Figure 3 Florescence emission spectrum of normal plasma: no
porphyrin like emission is observed. (The nonzero baseline is due
to scattered exciting light).
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Figure 4 Florescence emission spectrum of plasma of VP
patient: excitation, 400 nm and 625 indicates ﬂuorescence emission
maximum of 625 nm.
Porphyrins proﬁle by high performance liquid chromatography/electrospray 53This clearly shows the high incidence of positive consanguinity
among Egyptian population. Temtamy and Loutife [16] stated
that the rate of consanguineous marriages among general pop-
ulation in Egypt was 33% and in another studies carried out
by Hafez et al. [17] was 28.9% and by Temtamy et al. [18]
was 20–40%.
Six cases were diagnosed as porphyria patients. They in-
cluded one case of variegate porphyria (VP) and ﬁve cases of
porphyria Cutanea Tarda (PCT). Variegate porphyria (VP)is an autosomal dominant disorder. The disease has now been
reported worldwide and with the exception of South Africa
there is no racial or geographic predilection [19]. The variabil-
ity implicit in its name refers to the propensity of the disease to
present with neurovisceral symptoms, photosensitivity or both
in variable degrees. This agrees with our ﬁnding in case no. one
which presented with polyneuropathy, abdominal pain and
skin photosensitivity. Symptoms of VP are most common after
puberty but in rare homozygous cases of these porphyrias clin-
ical manifestations begin in childhood [20]. Our case was a six
years old male.
Neurological symptoms can be severely disabling and,
when the condition can not been diagnosed, may be fatal.
Abdominal pain, the most frequent symptom, is usually poorly
localized and may be accompanied by vomiting, constipation,
distention, and rarely diarrhea. Sympathetic overactivity may
result in tachycardia, hypertension, tremors, excessive sweat-
ing, urinary retention, cardiac arrhythmias, and sudden death.
Acute psychiatric manifestations and seizures may occur,
although these are limited to the period of the acute attack.
Seizures may be due to hyponatremia, which may be exacer-
bated by intravenous infusion of sodium-free dextrose. Periph-
eral neuropathy is due to axonal degeneration, primarily
affecting motor neurons, and can lead to respiratory and bul-
bar paralysis and death [21]. Porphyric crises are often induced
by precipitating factors such as inappropriate use of porphyri-
nogenic drugs, starving, excess of alcohol, infection and psy-
chological stress [22]. Skin manifestations are less frequently
observed in cold climate [1] which is not the case in our coun-
try. The cutaneous manifestation of VP i.e., blisters and fragil-
ity in light exposed skin areas is similar to that of porphyria
cutanea tarda (PCT) [19].
Porphyria cutanea tarda is a heterogenous group of por-
phyria which may be either acquired or inherited. It is the most
common of all the porphyrias [1]. Five cases out of 50 (10%)
studied patients were diagnosed with PCT. Typically por-
phyria cutanea tarda presents in adults and this was obvious
in our ﬁve cases. They were all adult males with mean age of
38.4 ± 6.02 years [1]. The sporadic subtype (75% of cases) is
most often identiﬁed in male patients without a family history
of the disease. The familial subtype (25% of cases) has an ear-
lier onset than does the sporadic subtype, and arises equally in
both sexes. It is transmitted as an autosomal-dominant mende-
lian disorder of low penetrance, attributable to a family-spe-
ciﬁc uroporphyrinogen decarboxylase (UROD) gene defect
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Figure 5 LC/MS/MS product ion spectrum of the (M+ H)+ ion of porphobilinogen (m/z 227 > 210) from urine of variegate porphyria
patient. the product ion is obtained by losing of NH3 group (17 m/z).
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Figure 6 LC/MS/MS product ion spectrum of the (M+ H)+ ion of coproporphyrin (m/z 655 > 596) from urine of VP patient. The
product ion is obtained from benzylic cleavage and loss of one acetyl group (59 m/z) another product m/z 53 obtained by losing a single
propionyl group and three methyl groups (118 m/z).
54 E. Fateen et al.[4]. Our ﬁve cases were suggested to have the sporadic subtype
of PCT since they had no reported family history of the dis-
ease. Cutaneous lesions on light exposed areas especially legs
and arms is found in almost all patients [4]. All our cases
had skin lesions on the legs or arms. Patients have increased
skin fragility on minor traumas. Hepatomegaly was found inall ﬁve cases. Patients with PCT display siderosis with widely
variable degrees of fatty damage and chronic inﬂammatory
changes [1]. Anemia also was found in all ﬁve PCT cases. Ane-
mia in these patients may be due to many factors like the
abnormal serum iron and ferritin concentrations, absorption
and turnover.
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Figure 8 LC/MS/MS product ion spectrum of the (M+ H)+ ion of hepta-carboxylporphyrin from PCT patient. (m/z 787 > 683) the
product ion is obtained from loss of acetyl group and a carboxyl group.
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Figure 7 LC/MS/MS product ion spectrum of the (M+H)+ ion of uroporphyrin from urine of PCT patient (m/z 831 > 727) the
product ion is obtained from loss of acetyl group and a carboxyl group. Another major product (767) is obtained by loss of H2O followed
by subsequent loss of protonated carboxylic group (64 m/z) another product (785) is produced from benzylic cleavage of protonated
carboxyl group (46 m/z).
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56 E. Fateen et al.Hemosiderosis is a contributing factor, it is seen in 80% of
liver biopsy specimens from patients with PCT. This may be
more exaggerated in cirrhotic patients [22].
Dark urine color was a sign in 32% of the whole group and
100% in the 6 diagnosed patients. It is due to excessive excre-
tion of porphyrinogens which are oxidized to porphyrins upon
exposure to light. PCT is often triggered by exposure to envi-
ronmental factors, alcohol consumption, estrogens, exposure
to pesticides, iron overload, and viral infections [23,24].
Red conjunctiva is found in two patients diagnosed as PCT
in this group. Red conjunctiva is expected in those cases due to
many factors, such as the increased capillary fragility and the
photosensitivity. Rare ocular complications have been re-
ported in porphyria cutanea tarda, such as ocular pain and
photophobia [10].
As regards the ﬂourometric screening for porphyria in plas-
ma of the six diagnosed cases, case one showed an emission
peak at 625 nm. This peak establishes the diagnosis of varie-coprotwentyMSMS01 #6397 RT: 21.32 AV: 1 NL: 2.94E4 microAU
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Figure 9 Chromatograms of coproporphyrin detection using HPLC–
the TIC of coproporphyrin showing an integrated peak at RT 21.52 min
of coproporphyrin at the same RT, showing the product masses (m/z 5
mass of coproporphyrin (m/z 655).the lower one shows PDA chr
wavelength 395 nm.gate porphyria. Hift et al. [6] demonstrated that for diagnosis
of the type of acute porphyria in the proband, plasma ﬂuores-
cence emission spectroscopy is a ﬁrst-line test because a peak at
624–626 nm establishes the diagnosis of variegate porphyria.
Also cases 2, 3, 4, 5 and 6 showed emission peak at 620 nm
which indicates the diagnosis of porphyria but does not distin-
guish the type of porphyria. Plasma ﬂuorescent spectrum is the
best initial test for diagnosis of cutaneous porphyrias, differen-
tiating between variegate porphyria and porphyria cutanea
tarda [25,26].
As regards the quantitative determination of urinary por-
phyrins by LC/MS/MS, case one showed high level of porpho-
bilinogen and coproporphyrin. High level of porphobilinogen
indicates the presence of acute attack of porphyria. Examina-
tion of urine for excess porphobilinogen is the essential ﬁrst-
line test for patients with a suspected attack of acute porphyria
[2]. Urinary coproporphyrin and porphobilinogen become
markedly elevated during acute attack of variegate porphyria450 500 550 600
ngth (nm)
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Figure 10 calibration curve of coproporphyrin showing the
equation used for quantitation of porphyrins in urine samples.
Porphyrins proﬁle by high performance liquid chromatography/electrospray 57[1]. Cases 2, 3, 4, 5 and 6 showed high level of 7-carbo-
xylporphyrin and uroporphyrin which indicates a case of
PCT. Smith et al. [27] stated that increased concentration of
uroporphyrin and 7-carboxylic porphyrins are found in the ur-
ine of PCT patients with lesser increases of coproorphyrin and
5- and 6-carboxylic porphyrins.
In this studywehave described the differentmethods used for
screening of porphyria: The ﬁrst method is screening in plasma
by ﬂuorescence scanning. Poh-Fitzpatrick has previously re-
ported the diagnostic usefulness of determining the ﬂuorescence
maxima of unextracted, native porphyrin-protein complexes in
patients plasma simply diluted with phosphate-buffered saline.
This method has been reliably used to differentiate patients with
erythropoietic protoporphyria from patients with porphyria
cutanea tarda or congenital erythropoietic porphyria by plasma
ﬂuorescence characteristic alone [11]. Patients with variegate
porphyria have a sharply deﬁned ﬂuorescence emission maxi-
mum at an excitation wavelength of 626 ± 1 nm [6].
The second method is urine porphyrin proﬁle analysis by
HPLC/ESI/MS/MS and we have shown that they are useful
in the differential diagnosis and proper management of por-
phyrias. It was useful in porphobilinogen measurement which
can be very helpful in patients who are suspected of having
acute neurovisceral porphyric attacks and also porphyrin
intermediates measurement which are diagnostic for porphyria
in suspected patient with skin photosensitivity [4]. The success-
ful application of HPLC/ESI/MS/MS to the analysis of por-
phyrins in biological and clinical materials depends on high
resolution HPLC system capable of complete separation of
the porphyrins. The mobile phase of such a system should also
be compatible with mass spectrometry. Mobile phase contain-
ing involatile buffer should be avoided. The reversed phase
gradient elution system using a mixture of acetonitrile, metha-
nol and 20 mM ammonium acetate/acetic acid buffer (pH 4)
reported here as mobile phase was able to separate all the nat-
urally occurring porphyrins in urine. Ammonium acetate is an
excellent mobile phase additive for reversed phase HPLC and
ammonium acetate/acetic acid buffer is a widely used mobile
phase in HPLC-MS analysis.
In this study we used also a comparative ESI/MS/MS tech-
nique called ion mapping experiment where direct infusion ofsamples in mass device is done. This technique consumes less
time and avoids the technical HPLC problems. On the other
hand, it revealed almost the same results. This technique was
designed for application by the Biochemical Genetics Depart-
ment team. Quantitative determination of urinary porphyrins
using HPLC/ESI/MS/MS and ion mapping techniques are
applicable for the differential diagnosis of porphyria types,
since each type has a characteristic porphyrins excretion pat-
tern. Quantitative determination of urinary porphyrins using
HPLC/ESI/MS/MS is a modiﬁcation for the method Stoev
et al. and ion mapping technique is a new techniques invented
by the research team at the Biochemical Genetics department.
The fragmentation pattern of the porphyrins is dominated
by cleavages of the side chain substituents. Analysis of the
product ion spectrum of a porphyrin thus allows the identiﬁca-
tion of the substituent groups. An acetic acid substituent char-
acteristically eliminates a COOH2 (46 mass units) group by
benzylic cleavage of the protonated CH2COOH group, while
a propionic acid substituent loses a CH2COOH (59 mass units)
group via benzylic cleavage of CH2CH2COOH. Porphyrins
with both acetic acid and propionic acid substituent show a
combination of both pathways. There are still many new por-
phyrin metabolites in nature awaiting identiﬁcation. HPLC/
MS/MS is a powerful technique for the sensitive and speciﬁc
characterization of these naturally occurring porphyrins.
Therefore the application of HPLC/ electrospray ionization
tandem mass spectrometry is the best method in the differen-
tial diagnosis of human porphyrias [28,29].5. Conclusion
Porphyrias are a group of inherited or acquired disorders of
certain enzymes in the heme bio-synthetic pathway. Most por-
phyria symptoms are nonspeciﬁc and occur intermittently;
resulting frequently in missed diagnosis since the disease itself
is rather rare. Plasma ﬂuorescence scanning is a simple proce-
dure that can be used as screening test to detect porphyria pa-
tients that require quantitation of urinary porphyrins as a
second step. Quantitative determination of urinary porphyrins
using HPLC/ESI/MS/MS and ion mapping techniques are
applicable for the differential diagnosis of porphyria types,
since each type has a characteristic porphyrins excretion pro-
ﬁle. Quantitative determination of urinary porphyrins using
HPLC/ESI/MS/MS is a modiﬁcation for the method Stoev
et al. and ion mapping technique is a new technique invented
by the research team at the Biochemical Genetics department.
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